Company Overview and News

 
Admedus completes placement to strategic cornerstone investor Star Bright Group

2018-09-18 proactiveinvestors.com.au
Admedus Limited (ASX:AHZ) has completed the placement of more than 70 million shares to Hong Kong-based significant investor Star Bright Group.
AHZ

 
Admedus receives $3.425 million in funds from further Star Bright placement

2018-09-05 proactiveinvestors.com.au
Admedus Limited (ASX:AHZ) has received more than $3.425 million in funds from a placement of more than 26 million shares to new Hong Kong-based significant investor Star Bright Holding Ltd.
AHZ

 
Admedus secures strategic cornerstone investor from Hong Kong

2018-09-02 proactiveinvestors.com.au
Admedus Ltd (ASX:AHZ) continues to build its relationship with strategic investor and shareholder Star Bright Holding Ltd, who will increase its holding to 19.99%.
AHZ

 
Admedus extends successful distribution deal for medication delivery pumps

2018-08-09 proactiveinvestors.com.au
Admedus Ltd (ASX:AHZ) has renewed its exclusive distribution agreement with Utah-based Summit Medical Products Inc for a further eight years.
AHZ

 
Admedus has capital raising news imminent, granted ASX trading halt

2018-08-02 proactiveinvestors.com.au
Admedus Ltd (ASX:AHZ) has been granted a trading halt by the ASX pending news of a capital raising.
AHZ

 
Admedus commences animal trials for heart valve device

2018-07-11 proactiveinvestors.com.au
Admedus Ltd (ASX:AHZ) has commenced animal trials by completing the first successful live implantation of its unique single-piece aortic heart valve.
AHZ

 
Admedus signs exclusive distribution agreement in Italy for its unique heart tissue product

2018-07-09 proactiveinvestors.com.au
Admedus Ltd (ASX:AHZ) has signed an exclusive distribution agreement with Medical Instruments S.p.A. to market and distribute its clinically-superior ADAPT® technology in Italy.
AHZ

 
Admedus signs exclusive distribution agreement in Italy for its unique heart tissue product

2018-07-09 proactiveinvestors.com.au
Admedus Ltd (ASX:AHZ) has signed an exclusive distribution agreement with Medical Instruments S.p.A. to market and distribute its clinically-superior ADAPT® technology in Italy.
AHZ

 
Admedus board members stand with shareholders and buy shares

2018-06-29 proactiveinvestors.com.au
Admedus Ltd (ASX:AHZ) has issued $200,000 worth of shares to three of its board members as part of the recent capital raising priced at 30 cents.
AHZ

 
Admedus progressing towards securing $18 million investment for immunotherapies division

2018-06-27 proactiveinvestors.com.au
Admedus Ltd (ASX:AHZ) has made progress towards securing a long-term funding arrangement for Admedus Vaccines Pty Ltd with Hong Kong investor Star Bright Holding Ltd by executing a Memorandum of Understanding (MOU).
AHZ

 
Admedus raises $2.76 million from share purchase plan

2018-06-04 proactiveinvestors.com.au
Admedus Ltd (ASX:AHZ) shareholders have subscribed for 9.2 million shares priced at 30 cents raising $2.76 million in funding under a share purchase plan (SPP).
AHZ

 
Admedus files three new patents in the US for heart valve device

2018-05-23 proactiveinvestors.com.au
Admedus Ltd (ASX:AHZ) has filed three new provisional patent applications in the US as part of its transcatheter aortic valve replacement (TAVR) research and development project.
AHZ

 
Admedus progressing to animal trials of its unique heart valve device

2018-05-22 proactiveinvestors.com.au
Admedus Ltd (ASX:AHZ) is entering the next stage in the development of its Transcatheter Aortic Valve Replacement (TAVR) project by signing an agreement to commence animal trials in a leading European laboratory.
AHZ

 
Admedus signs deal to market its heart tissue products in Spain and Portugal

2018-05-17 proactiveinvestors.com.au
Admedus Ltd (ASX:AHZ) has signed an exclusive distribution agreement with leading healthcare group, Cardiva, to market and supply its ADAPT® tissue products in Spain and Portugal.
AHZ

 
Admedus using capital raised to advance product development and share price growth

2018-05-15 proactiveinvestors.com.au
Admedus Ltd (ASX:AHZ) chief executive Wayne Paterson updates Proactive Investors on product development, a major agreement, key executive appointments, and strategic financing decisions.
AHZ

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...